Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 313-327

  Kim, Yoojin ^a   Babu, Ambika R ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

Glucosuria; Inhibitors; Kidney; Oral diabetes agent; SGLT2; Sodium glucose cotransporter type 2; Weight loss

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIGOXIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; IPRAGLIFLOZIN; METFORMIN; MOLECULE TRANSPORT AGENT; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REMOGLIFLOZIN ETABONATE; SIMVASTATIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; VALSARTAN; WARFARIN;

BLADDER CANCER; BLOOD PRESSURE; BONE DENSITY; BREAST CANCER; CANCER RISK; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ELECTROLYTE BLOOD LEVEL; EXERCISE; FAINTNESS; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HEART RATE; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; POSITIONAL DIZZINESS; PYELONEPHRITIS; QT INTERVAL; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME; VAGINAL PRURITUS; VITAMIN BLOOD LEVEL; VULVA PRURITUS; VULVOVAGINAL DISEASE; WEIGHT REDUCTION;

EID: 84872322425     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s22545     Document Type: Review

References (44)

1. American Diabetes Association. Diabetes Statistics. Data from the 2011National Diabetes Fact Sheet. Available from: http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed May 30, 2012.
2. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
3. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300(1):C14-C21.
4. Sabino-Silva R, Mori RC, David-Silva A, Okamoto MM, Freitas HS, Machado UF. The Na (+)/glucose cotransporters: from genes to therapy. Braz J Med Biol Res. 2010;43(11):1019-1026.
5. Wright EM. Renal Na (+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10-F18.
6. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133-141.
7. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873-2882.
8. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32-43.
9. Tabatabai NM, Sharma M, Blumenthal SS, Petering DH. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83(1):e27-e30.
10. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434.
11. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31-38.
12. Najafian M, Jahromi MZ, Nowroznejhad MJ, et al. Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats. Mol Biol Rep. 2012;39(5):5299-5306.
13. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320(1):323-330.
14. Dobbins RL, O'Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2012;14(1):15-22.
15. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520-526.
16. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(4):357-365.
17. Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2inhibitor, in healthy subjects. Diabetes Obes Metab. 2011;13(8):770-773.
18. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513-519.
19. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-657.
20. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.
21. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
22. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):20-31. http://jcem.endojournals.org/.
23. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022.
24. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-938.
25. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-1662.
26. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12(6):510-516.
27. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-415.
28. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-456.
29. Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther. 2011;2(3):123-132.
30. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33(11):1798-1808.
31. European Medicine's Agency. Summary of opinion: Forziga. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002322/WC500125684.pdf. Accessed May 30, 2012.
32. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163-177.
33. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47-54.
34. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2inhibitor. Nat Rev Drug Discov. 2011;10(9):645-646.
35. United States Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin tablets, 5 and 10mg sponsor: Bristol-Myers Squibb. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. Accessed May 30, 2012.
36. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7): 669-672.
37. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539-545.
38. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6): 1232-1238.
39. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31(12):839-851.
40. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219-1227.
41. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2inhibitors. Diabetes Obes Metab. 2012;14(1):83-90.
42. Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94-96.
43. Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341(3):692-701.
44. Nair S, Wilding JP. Sodium glucose co transporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34-42. http://jcem.endojournals.org/.